
Roche and Zealand drug shows 9.2% mean body weight reduction
Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More













